Sign up
Pharma Capital

Summit Therapeutics unveils second series of compounds which could kill gonorrhoea bacteria

Summit revealed back in April that it had identified a series of compounds which it thinks could treat the sexually transmitted infection, and it announced a second series on Monday
bacteria
Gonorrhoea is notoriously hard to treat because of its high resistance to antibiotics

Summit Therapeutics PLC (LON:SUMM) has discovered a second series of “promising” compounds which it believes could be used to treat gonorrhoea.

Back in April, the AIM-quoted group revealed it had found a different series of new mechanism antibiotics for the sexually transmitted infection which is notoriously difficult to treat because of its high resistances rates.

READ: Summit discovers new potential antibiotics for gonorrhoea

Initial research has suggested that these new compounds have the characteristics to kill the bacteria, including the resistant strains.

“Gonorrhoea poses an urgent threat as the world approaches an era of untreatable disease due to increasing resistance against the last recommended treatment option," said Summit’s president of R&D, David Roblin.

“Having two novel approaches with the potential to combat gonorrhoea means Summit has an opportunity to meaningfully contribute to the fight against this significant worldwide health threat.”

Both series of compounds were identified using Summit’s Discuva platform – a genetics-based technology used for the discovery and development of new antibiotics against infections generally associated with antibiotic resistance.

Roblin added: “We believe our Discuva Platform has the potential to radically change antibiotic drug discovery and development.”

Currently there is only on treatment option for gonorrhoea recommended by the US Centres for Disease Control, although the bacteria’s resistance is rising all the time.

The World Health Organisation estimates there are 78mln new cases of the infection around the world every year.

Summit shares edged 0.8% to 194p.

View full SUMM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.